Reclassification recommendations for drug in 'magic mushrooms'
Wednesday, September 26, 2018 - 16:40
in Health & Medicine
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug -- one with no known medical potential -- to a schedule IV drug such as prescription sleep aids, but with tighter control.